06:31 AM EDT, 04/22/2026 (MT Newswires) -- Marinomed Biotech (MARI.VI) said Wednesday that it will expand its business to include pharmaceutical compounding services.

Using its Marinosolv technology, the Austrian biotech company will formulate compounded formulations tailored to the specific needs of patients or physicians to improve adherence, tolerability, and overall outcomes.

Several customers are expected to commission services based on the Marinosolv technology in the short to medium term, with first revenue expected in the fourth quarter of 2026 or the start of 2027.

Marknadsöversikt

1 DAG %

Senast

1 mån